KDA Group Announces the Appointment of Dr. Giuseppe D’Aprano as Chief Scientific Officer

Tickers: XTSX:KDA
Tags: #Mining

Thetford Mines, Quebec / TheNewswire / June 26, 2019 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation“) is proud to announce that Dr. Giuseppe D’Aprano is appointed to the Corporation’s management team as Chief Scientific Officer (CSO) as of June 26, 2019.

With the creation of this new position, the Corporation and its subsidiary CanNorth Medic Inc. (“CanNorth“), take a significant step further in executing on its strategy to become a global leader in cannabis cultivation with a vision to offer patients innovative and high-quality cannabis-based products for medical use.

Holder of a Ph.D. in Chemistry from University de Montreal, Dr. Giuseppe D’Aprano is the author and co-author of 22-scientific peer-reviewed articles published in various international scientific journals of high reputation. Following his scientific journey, Dr. D’Aprano has worked in the pharmaceutical industry over the last 20 years. Seasoned leader, he held various positions in scientific affairs (quality assurance and regulatory). He was then called to play strategic roles where he consolidated a portfolio of pharma products by patents due diligence, and subsequently, by complex financial analyses and business cases of several hundred products.

“Giuseppe joined us last autumn and he immediately made his presence felt by both his experience and professionalism. Giuseppe’s promotion is part of the Corporation’s and CanNorth’s mission to develop innovative and high-quality cannabis-based products for medical use. The legalization of medical cannabis production in Canada will lead to advanced scientific research to identify the most active therapeutic products as well as their ideal administration routes. The strategic, commercial and scientific skills of Giuseppe in addition to his leadership will allow the Corporation to take off in an industry still in effervescence,” said Marc Lemieux, President and Chief Executive Officer of KDA.

In his new role, Dr. Giuseppe D’Aprano and his team will be responsible for the development strategy of the cannabis products with the collaboration of various Key Opinion Leaders (KOLs), Good Manufacturing Practices (GMP) certification, compliance and portfolio management of the Corporation.


KDA is a leading innovation and specialized solution provider in the pharmaceutical market. Today it is a respected name for quality and expertise among the different stakeholders in the pharmaceutical and medical sector. Its management team is guided by a vision of continuing to lead the way in Quebec while extending operations across Canada and internationally. Additional information on the Corporation is available at www.groupekda.ca and on SEDAR at www.sedar.com.

– 30 –


This press release from KDA contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments as well as other factors that management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.


Marc Lemieux

Chief Executive Officer

514 622-7370

[email protected]

Copyright (c) 2019 TheNewswire – All rights reserved.

Comments are closed.

Free newsletter for stock pics, interview transcripts & investing ideas